ITMN-191: Phase Ib started

ITMN and ROG began the multiple-ascending dose Phase Ib MAD trial in 40 patients with chronic HCV genotype 1 infection to evaluate oral ITMN-191 given as a monotherapy twice or thrice daily for 14 day...